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Economic Evaluations and Randomized Trials in Spinal
Disorders: Principles and Methods
Ingeborg Korthals-de Bos, PhD,* Maurits van Tulder, PhD,*
Hiske van Dieten, MSc,† and Lex Bouter, PhD*
Study Design. Descriptive methodologic recommenda-
tions.
Objective. To help researchers designing, conducting,
and reporting economic evaluations in the field of back
and neck pain.
Summary of Background Data. Economic evaluations
of both existing and new therapeutic interventions are
becoming increasingly important. There is a need to im-
prove the methods of economic evaluations in the field of
spinal disorders.
Materials and Methods. To improve the methods of
economic evaluations in the field of spinal disorders, this
article describes the various steps in an economic evalu-
ation, using as example a study on the cost-effectiveness of
manual therapy, physiotherapy, and usual care provided by
the general practitioner for patients with neck pain.
Results. An economic evaluation is a study in which
two or more interventions are systematically compared
with regard to both costs and effects. There are four types
of economic evaluations, based on analysis of: (1) cost-
effectiveness, (2) cost-utility, (3) cost-minimization, and
(4) cost-benefit. The cost-utility analysis is a special case
of cost-effectiveness analysis. The first step in all these
economic evaluations is to identify the perspective of the
study. The choice of the perspective will have conse-
quences for the identification of costs and effects. Sec-
ondly, the alternatives that will be compared should be
identified. Thirdly, the relevant costs and effects should
be identified. Economic evaluations are usually per-
formed from a societal perspective and include conse-
quently direct health care costs, direct nonhealth care
costs, and indirect costs. Fourthly, effect data are col-
lected by means of questionnaires or interviews, and rel-
evant cost data with regard to effect measures and health
care utilization, work absenteeism, travel expenses, use
of over-the-counter medication, and help from family and
friends, are collected by means of cost diaries, question-
naires, or (telephone) interviews. Fifthly, real costs are
calculated, or the costs are estimated on the basis of real
costs, guideline prices, or tariffs. Finally, in the statistical
analysis the mean direct, indirect, and total costs of the
alternatives are compared, using bootstrapping tech-
niques. Incremental cost-effectiveness ratios are graphi-
cally presented on a cost-effectiveness plane and accept-
ability curves are calculated.
Conclusion. Economic evaluations require specific
methods. These recommendations may be helpful in im-
proving the quality of economic evaluations of new and
existing therapeutic interventions in the field of spinal
disorders. [Key words: economic evaluations, cost-effec-
tiveness, methodology, musculoskeletal disorders] Spine
2004;29:442–448
As a result of the limited availability of financial re-
sources, there is an increasing demand to improve the
efficiency of health care, and an increasing number of
economic evaluations are performed to meet this de-
mand. Economic evaluation in health care can be defined
as the comparative analysis of alternative interventions
in terms of both their costs and consequences (risks).1,2
The main tasks involved in any economic evaluation are
identifying, measuring, valuing, and comparing the costs
and consequences of new or existing interventions.1,2
The central question in any type of economic evaluation
is whether the extra effects of an intervention are worth
the extra costs. An intervention with high costs can still
be efficient, provided that the effects of the intervention
are also substantial. In other words, the intervention
with the lowest costs is not necessarily the most efficient.
A variety of preventive, diagnostic, and therapeutic
interventions are commonly used for patients with spinal
disorders, and numerous randomized trials and system-
atic reviews have evaluated the effectiveness of these in-
terventions. Because spinal disorders have a major im-
pact on society in terms of total health care expenditure,
work absenteeism, and disablement, it is also important
to obtain insight into the efficiency of these interventions.
As yet, only a few reports on full economic evaluations in
this field have been published and their methodologic
quality is generally poor.3,4 This article discusses the the-
ory and the methodology underlying economic evalua-
tions in an attempt to improve the quality of future eco-
nomic evaluations in the field of spinal disorders. An
example is used to illustrate an economic evaluation that
we recently performed alongside a pragmatic randomized
controlled trial in which patients with neck pain were
treated with manual therapy, physiotherapy, or continued
care provided by the general practitioner (GP).5,6
Economic Evaluation
Economic evaluations can be subdivided into partial
evaluations and full evaluations (Table 1). Most eco-
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nomic evaluations are partial evaluations, in which only
the costs or costs and effects of one intervention are de-
scribed, or in which the costs of two or more interven-
tions are compared.1 Only with full economic evalua-
tions, in which the costs and effects of two or more
interventions are compared, can questions about effi-
ciency be answered. This article focuses on full economic
evaluations performed concurrent with randomized con-
trolled trials. Examples of partial evaluations are two
observational studies in which the costs of back and neck
pain have been estimated.7,8
In Table 1, the four most commonly used methods for
full economic evaluations are listed.1 The designs of
these studies are similar, and the main difference is the
outcome measures that are used to determine efficiency.
Cost-Effectiveness Analysis
Cost-effectiveness analysis involves the difference in costs
of two or more interventions related to the difference in
effects. The effects are usually primary clinical outcomes,
i .e. , intensity of pain, disability, and general
improvement.
Cost-Utility Analysis
Cost-utility analysis is a special case of cost-effectiveness
analysis. The difference in costs of two or more interven-
tions is related to the difference in utilities. A utility refers
to the preference that individuals or society may have for
any particular set of health outcomes. A cost-utility anal-
ysis is particularly useful because it allows for quality-of-
life adjustments to a given set of intervention outcome
measures, and it provides a generic outcome measure for
comparison of costs and outcomes between different in-
terventions and diseases. The results of cost-utility anal-
yses are typically expressed in terms of costs per quality-
adjusted life-year (QALY) or disability-adjusted life-year
(DALY).
Cost-Minimization Analysis
This economic evaluation is a special form of cost-
effectiveness analysis, in which the effects of the interven-
tions being compared are equal. Consequently, only the
difference in costs is evaluated.
Cost-Benefit Analysis
The difference in costs of two or more interventions is
related to the difference in financial benefits. Sometimes
it cannot be assured that the consequences of alternative
interventions and for different diseases are identical. In
addition, it is sometimes not possible to reduce the out-
comes of interest to a single effect that is common to both
interventions. The consequences of an intervention may
then be expressed in terms of their financial benefits to
facilitate comparison between the interventions; for ex-
ample, using the willingness-to-pay principle.
It may not always be possible to predict in advance
which type of economic evaluation will be performed,
because this may depend on the results of an associated
clinical evaluation. Furthermore, various approaches are
sometimes used simultaneously, because each individual
approach explores a different dimension. However, cost-
effectiveness and cost-utility analyses are the most com-
monly used types of economic evaluation in the field of
spinal disorders.
Study Design
The design of an economic evaluation consists of several
steps:1,2
1. Identification of the perspective
2. Identification of the alternatives
3. Identification, measurement, and valuation of
effects
4. Identification, measurement, and valuation of
costs
5. Statistical analysis
Identification of the Perspective. An economic evaluation
can be performed from different perspectives, and the
perspective chosen determines the design of the evalua-
tion.1,2 An economic evaluation is usually performed
from a societal perspective, in which all relevant costs
and effects are measured, regardless of who pays the
costs and who benefits from the effects. However, an
economic evaluation can also be performed from a nar-
rower perspective, such as the perspective of insurance
companies, hospitals, physicians, or patients. From the
perspective of patients, for example, only the out-of
pocket expenses for over-the-counter medication or vis-
its to alternative and complementary therapists are
important.
In the economic evaluation comparing manual ther-
apy, physiotherapy and continued care provided by the
Table 1. Distinguishing Characteristics of Health Care Evaluations1





Is there a comparison of two
or more alternatives?
No Outcome description Cost description Cost-outcome description
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GP for patients with neck pain, a societal perspective was
chosen. All direct and indirect costs were included in the
economic evaluation.6
Identification of the Alternatives. In an economic evalua-
tion, two or more preventive, diagnostic, or therapeutic
interventions are compared. The experimental interven-
tion should be compared with another intervention, pref-
erably to usual care or the best available alternative.1,2
The comparison intervention, however, can also be the
cheapest alternative, a rival product, a placebo, or no
treatment. Ideally, a new intervention should only be
implemented if it is proven to be more efficient than the
best available alternative. Coexisting interventions can
also be compared in an economic evaluation to deter-
mine the most efficient intervention for the patients.
There are strict regulations regarding the introduction of
new medication, including the choice of the comparative
intervention in pharmacoeconomic evaluations.9–11 As
yet there are no such regulations for other new products
or nonpharmaceutical interventions (e.g., new exercise
regimes or new surgical techniques).
In the neck pain economic evaluation, three interven-
tions (manual therapy, physiotherapy, and continued
care provided by the GP) were compared. These inter-
ventions are the most commonly applied conservative
methods of treatment for patients with neck pain in The
Netherlands. At the start of the trial, it was unclear
which intervention was the best available treatment op-
tion for patients with neck pain.6
Identification, Measurement, and Valuation of Effects. Before
performing an economic evaluation, the relevant effects
must be identified. In many cases, the economic evalua-
tion will be conducted alongside a clinical study; for in-
stance, a randomized clinical trial. The primary outcome
measures of the clinical trial are also used in the eco-
nomic evaluation. The outcome measures in trials on
spinal disorders usually include the following domains:
pain, disease-specific function, generic health status,
work disability, and patient satisfaction.12
In addition to disease-specific outcome measures,
most economic evaluations also include generic outcome
measures. These generic outcome measures are usually
less responsive but make it possible to compare the out-
comes of a range of interventions for different diseases.
Examples of health profiles are the SF-36,13 the Notting-
ham Health Profile (NHP),14 and the Sickness Impact
Profile (SIP).15 Examples of commonly used health in-
dexes are the EuroQol16 and the Health Utility Index
(HUI).17 A health index can be used to calculate utilities,
in which the effects are expressed as QALYs.18 Some-
times, DALYs are used. A DALY combines time lived
with a disability and the time lost because of premature
mortality.19
The economic evaluation of treatments for neck pain
was conducted alongside a randomized clinical trial in
which various outcomes were measured. Perceived re-
covery was measured on a 6-point scale, ranging from
“completely recovered” to “much worse.” The severity
of the main symptom and pain intensity were measured
on an 11-point numerical rating scale, ranging from 0 to
10. The EuroQol was used to calculate utilities. Patients
completed self-report questionnaires at baseline and af-
ter 3, 7, 13, 26, and 52 weeks.6
Identification, Measurement, and Valuation of Costs. The
costs that are relevant for economic evaluations can be
subdivided into direct health care costs, direct nonhealth
care costs, and indirect costs.1 Direct health care costs
are the costs of activities within the formal health care
system that are directly related to the disease or disorder
at issue; for instance, costs of physiotherapy, manual
therapy, general practice care, medication, orthopedic
care, and hospital admission. Direct nonhealth care costs
are the costs of activities outside the formal health care
system that are directly related to the disease or disorder.
Examples are travel expenses to and from the hospital,
the costs of over-the-counter medication, the cost of in-
formal health care (care provided by the family), and the
costs of devices. Indirect costs are costs that have no
direct connection with the medical interventions, but are
a consequence of it. Indirect costs within the health care
system are the costs patients incur during the life-years
gained. Indirect costs outside the health care system are
the costs of production losses caused by work absentee-
ism, work disability, or death of a patient. Indirect costs
can be calculated for patients with or without a paid job.
To measure the direct and indirect costs, information
about the utilization of health care must be collected, for
which various methods exist, such as questionnaires, di-
aries, interviews, patient files, and insurance company
records. Typically, several methods are used simulta-
neously. The use of routine databases (i.e., in a hospital)
may not always provide the necessary information, and
the validity and reliability of the databases may not be
very high. Ideally, the relevant data are collected pro-
spectively; for example, by means of cost diaries, in
which patients record every visit to a physician or ther-
apist, the medication they use, and any work-
absenteeism or inability to perform daily activities result-
ing from the disease at issue.20
To value medical consumption a number of prices can
be used. The best way is to calculate real costs for at least
the most important cost components. With this method
the costs of personnel, materials, office space, deprecia-
tion, and overheads are charged to each intervention sep-
arately. In practice, however, it is not always possible to
calculate real costs because of the limited availability of
data. For example, to calculate the real costs of physio-
therapy for low back pain, one would need to accurately
calculate for each treatment session the costs of the phys-
iotherapist, the costs of the materials used (for example
the costs of towels, exercise equipment, etc.), and the
costs of the office space and exercise room. Obviously,
these costs are often difficult to calculate. Sometimes real
costs are not calculated for practical reasons, i.e., the
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enormous amount of time involved. There are some al-
ternatives for the use of real costs, one of which is the use
of tariffs. Tariffs are the result of negotiations between
professional health care organizations and the govern-
ment, and do not necessarily represent the real costs.
Sometimes a shadow price can be used to estimate costs;
for instance, for care provided by family or friends or if
available guideline prices (based on real costs calcula-
tion) can be used.
The indirect costs of spinal disorders are usually sub-
stantial. Therefore, it is important that they are correctly
estimated. There are two methods that can be used to
evaluate production losses: the human capital approach
(HCA)2 and the friction cost method (FCM).21 The HCA
is the most frequently used method, in which the indirect
costs are based on the total expected production losses
for an individual worker. The productivity losses occur
from the moment of absence until full recovery, and if no
recovery, until the moment of death or retirement.2 The
HCM does not take the replacement of the sick employee
(at a certain maximum of work absenteeism) into ac-
count. The FCM is based on the principle that the total
production losses depend on the time an organization
needs to replace a sick employee, the so-called friction
period.21
Both methods do not take into account the reduced
productivity of employees at their work. This is espe-
cially relevant for chronic spinal disorders in which pe-
riods of reduced productivity alternate with illness re-
lated absence. Kessler and colleagues recently developed
a self-report instrument to estimate the workplace costs
of health problems in terms of reduced job performance,
sickness absence, and work-related accidents. This in-
strument not only focuses on work absenteeism but also
focuses on the reduced job performance of patients with
a paid job and patients without a paid job.22 The number
of days of work absenteeism or inability to perform daily
activities must be valued for which the wages of the pa-
tients can be used. To make the indirect costs transparent
for other situations/countries, it is important to report
the number of work absenteeism days separately from
the indirect costs.
The neck pain economic evaluation was performed
from a societal perspective. Direct and indirect costs
were measured by means of cost diaries for a total fol-
low-up of 52 weeks. Direct costs included costs of visits
to the physiotherapist, manual therapist, and GP, and
hospitalization, surgery, and medication. Indirect costs
were costs of work absenteeism for patients with a paid
job and the inability to perform normal daily activities
for all patients. As an example, Table 2 presents an over-
view of different cost components and real costs used in
the economic evaluation for patients with neck pain. The
indirect costs in this economic evaluation were calcu-
lated according to the FCM, in which work absenteeism
per patient is restricted to a maximum number of days
(122 days).6
Statistical Analysis of Costs
Economic evaluations require specific statistical tech-
niques.23,24 In a full economic evaluation, the costs and
effects of two or more interventions are compared. The
first step is to analyze the costs and the effects separately.
Subsequently, the interventions are compared to deter-
mine whether the differences in costs and effects with a
95% confidence interval (CI) are statistically significant.
The analysis of cost data are complicated by the typ-
ical skewness or nonnormality of the data, which is usu-
ally caused by high costs incurred by a few patients. The
nonnormality of the distribution of cost data should be
taken into account in the analysis. Despite the usual skew-
ness in the distribution of costs, it is the arithmetic mean
that is the most informative measure for health care policy-
makers.23,24 Measures other than the arithmetic mean pro-
vide no information about the total cost of treating all pa-
tients. In the literature, various methods that can be used to
deal with the nonnormality of the cost data have been de-
scribed, such as Student’s t test, a t test on log-transformed
data, and truncation and nonparametric rank test (such as
Mann-Whitney/Wilcoxon).25–27
The preferred method for the analysis of cost data are
bootstrapping, which does not make any assumptions
regarding the normality of the data, the equality of the
variances or the shape of the distributions.28 Bootstrap-
ping is a data-based simulation method and uses the ob-
served distribution of the cost data. It is therefore appro-
priate for any distribution of data but is especially useful
when distributions are skewed and traditional statistical
methods may fail. Patients are randomly chosen from a
study population. The number of randomly chosen pa-
tients is usually the same as the patients in the study
population. The sampling is performed with replace-
ment, indicating that a patient can be chosen more than
Table 2. Prices Used in the Economic Evaluation of
Treatments for Patients With Neck Pain6
Euro
Direct health care costs
General practitioner (visit of max. 20 min)* 16.60
Manual therapist (visit of max. 45 min)** 25.90
Physiotherapy (visit of max. 30 min)* 18.15
Outpatient appointment* 40.85
Hospitalisation (per day)* 235.95
Cesar exercise therapist (per visit)* 17.70
Professional home care (per hour)* 22.70
Direct nonhealth care costs
Alternative therapist (per visit)*** 27.20
Home care (per hour)* 7.94
Help from partner/friends (per hour)* 7.94
Travel expenses (per km)* 0.11
Indirect costs
Absenteeism paid labor (per day)† —
Absenteeism unpaid labor (per hour)* 7.94
Euro 1  US $0.90.
* Guideline price according to recently published Dutch guidelines.
** Tariff.
*** Price according to professional association.
† Indirect costs for paid labor were calculated on the basis of a mean income
of the Dutch population according to age and sex.
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once from the study population. For each resample, the
statistics of interest are calculated. The number of sam-
ples will depend on the measure of interest. The distri-
bution of these values of the statistic provides an approx-
imation to its population sampling and can be used to
calculate CIs.28,29 There are various methods that can be
used to calculate bootstrapped CIs for differences in
costs. Currently, the preference is for CIs obtained by
bias-corrected and accelerated (BCA) bootstrapping.28
In the neck pain economic evaluation, differences in
costs were calculated and CIs were obtained by BCA
bootstrapping. The mean total costs per patient for man-
ual therapy (Euro 447) were one third of the mean total
costs for physiotherapy (Euro 1,297) and continued care
provided by the GP (Euro 1,379). These differences were
statistically significant for manual therapy compared
with physiotherapy (mean difference: Euro, 850; 95%
CI: 2,258; 239) and for manual therapy compared to
continued care provided by the GP (mean difference:
Euro, 932; 95% CI: 1,932; 283).6
Incremental Cost-Effectiveness Ratio. In an economic eval-
uation, the costs and effects of two interventions can be
directly evaluated by a cost-effectiveness ratio that indi-
cates what additional investments are necessary to gain
additional effects. Figure 1 presents a graph of the poten-
tial outcomes of the cost-effectiveness ratios.30 Note that
this figure can also be used for cost-utility ratios in which
effects are expressed as utilities.
If an intervention is more effective and less costly than
the alternative intervention to which it is compared, the
more effective and less costly intervention is dominant
and will obviously be preferred (Q-SE). If the alternative
intervention is less effective and more costly, the old in-
tervention will be preferred (Q-NW). If an intervention is
more effective and more costly (Q-NE) or less effective
and less costly (Q-SW), it is not immediately clear which
intervention should be preferred, and an incremental
cost-effectiveness ratio, cost-effectiveness plane, accept-
ability curve, or net health benefit should be calculated.
The CIs for the incremental cost-effectiveness ratio
can be calculated using the bias-corrected percentile
method.31,32 The interpretation of a cost-effectiveness
ratio with a 95% CI is difficult, and numerous problems
associated with an incremental cost-effectiveness ratio
and its 95% CI have been described.33,34 New methods
that try to avoid these problems have been developed; for
example, to present the results as a net health benefit or
an acceptability curve, which shows the probability that
a treatment is cost-effective at a specific ceiling ratio.35
In the neck pain economic evaluation, incremental
cost-effectiveness ratios were calculated. Manual therapy
was more effective and less costly than physiotherapy
and continued care provided by the GP. For example, the
incremental cost-effectiveness ratio for manual therapy
compared to physiotherapy for pain intensity was 757.
Indicating that manual therapy has a better effect on pain
intensity with saving in costs (757) compared to phys-
iotherapy. Figure 2 shows that 98% of the incremental
cost/effect pairs on the cost-effectiveness plane for this
ratio were located in the southeast quadrant (lower costs
and better effects). Therefore, it was concluded that man-
ual therapy was clearly dominant over physiotherapy.6
Sample Size Calculations
As stated previously, economic evaluations are often per-
formed alongside a randomized clinical trial. Sample
sizes in these trials are typically calculated to detect clin-
ically relevant differences in primary effect measures. To
calculate the sample size for an economic evaluation,
assumptions have to be made about the maximum
threshold value that will be accepted to obtain additional
effects or acceptable costs per outcome.36 It can be as-
sumed that the sample size required in an economic eval-
uation is very large, because of the large variation in cost
data compared with clinical effect measurements.34
Therefore, if sample size calculations are performed for
economic evaluations, then the clinical trial may become
too expensive, because of the large increase in the num-
ber of patients needed, or it might be unethical to include
Figure 1.. Cost-effectiveness
plane.30Q-NW, Northwest quad-
rant; Q-NE, Northeast quadrant;
Q-SE, Southeast quadrant; Q-SW,
Southwest quadrant.
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more patients than are needed to prove clinical effective-
ness.37 Consequently, clinical trials will typically be un-
derpowered for economic evaluations, even if the main
clinical comparison is appropriately powered.34
In the neck pain economic evaluation, the number of
patients needed was based on a clinically relevant differ-
ence. No separate sample size calculation was performed
for the economic evaluation. In this trial, manual therapy
proved to be cost-effective, and the sample size of the
clinical trial turned out to be large enough for the eco-
nomic evaluation.6
Sensitivity Analysis. The large number of assumptions
that are made in most economic evaluations may
strongly influence the results. It is customary to perform
a sensitivity analysis in which the most important as-
sumptions are varied to evaluate their impact on the con-
clusions.38 The ranges, and arguments for selecting these
ranges, must be described. Briggs and Sculpher distin-
guish four types of uncertainty relating to: data sources
of the study, extrapolation, the generalizability of the
study results, and application of the appropriate analyt-
ical methods.39
A one-way sensitivity analysis can be performed, in
which the effect of varying a single variable on the con-
clusions is explored. A multiway sensitivity analysis,
sometimes called a scenario analysis, varies more vari-
ables at the same time. The results of the sensitivity anal-
ysis will demonstrate the robustness of the findings and
will help to improve the generalizability of the economic
evaluation.40
In the neck pain economic evaluation, a sensitivity
analysis was performed by not using data on the patients
who received surgery or were admitted to hospital. The
sensitivity analysis showed the same results as the main
analysis: manual therapy was more cost-effective than
physiotherapy and continued care provided by the GP.6
Modeling
Randomized trials in the field of spinal disorders usually
have a follow-up of less than 1 year, although a few
recent trials have included follow-up duration up to 3 or
5 years. If one is interested in estimating the economic
impact of an intervention over a longer period than the
time horizon of the trial, decision-analytic or microsimu-
lation models can be used. The methods for using
Markov models in health services research are well-
documented. In a Markov model, a possible prognosis of
a patient is split into a number of states. The probabilities
of transition between states, costs, and effects can be
varied over a specific timeframe. In a study, for example,
evaluating the cost-effectiveness of nonsteroidal antiin-
flammatory drug (NSAID) side effects are important. In a
randomized trial, the sample size may be too small to
display adverse effects. However, adverse effects may be
well-documented in the literature. A model simulation
gives the opportunity to incorporate costs of adverse ef-
fects in an economic evaluation.41–43
Conclusion
Economic evaluations are becoming increasingly impor-
tant in health care research. In many cases, economic
evaluations will be performed alongside clinical trials. It
is important that an economic evaluation is fully inte-
grated in the clinical trial and equally carefully designed.
The study protocol must include considerations with re-
gard to the perspective of the economic evaluation, iden-
tification, measurement and valuation of costs and ef-
fects, sample size, the power to detect relevant differences
in economic variables, and an adequate length of
follow-up.25
Spinal disorders are not only a tremendous medical
problem but also a socioeconomic burden. Economic
evaluations help to identify the most efficient preventive,
diagnostic, and therapeutic interventions for patients
with spinal disorders and should play an important role
in evidence-based medicine and health policy. Two re-
views of published reports of economic evaluations in
the field of low back pain concluded that the method-
ologic quality of the economic evaluations was poor.3,4
Figure 2. Incremental cost-
effectiveness plane for pain inten-
sity comparing manual therapy to
physiotherapy for neck pain.6
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Because policy-makers in their decision-making process
use economic evaluations, it is of utmost importance that
the information they provide is valid and reliable. Eco-
nomic evaluations must be based on a specific study de-
sign and require specific statistical techniques. The aim
of this article was to provide insight into the specific
methodologic aspects of an economic evaluation and to
present some practical guidelines for economic evalua-
tions in the field of spinal disorders in line with the cur-
rent state of the art. Hopefully, these recommendations
will be helpful for researchers in conducting and publish-
ing economic evaluations and for readers in critically
appraising them.
Key Points
● Economic evaluations of existing and new ther-
apeutic interventions are becoming increasingly
important.
● There is a need to improve the methods of eco-
nomic evaluations in the field of back and neck pain.
● Recommendations are provided for measuring,
valuing, and analyzing cost data.These recommenda-
tions may be helpful in designing and conducting eco-
nomic evaluations in the field of back and neck pain.
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